Agilent Technologies (A) is drawing fresh attention after the FDA approved its PD-L1 IHC 22C3 pharmDx test as the only companion diagnostic for certain esophageal and gastroesophageal junction cancers treated with pembrolizumab.

The FDA companion diagnostic approval arrives alongside a 4.77% 1 day share price return and a 2.32% 7 day share price return. However, the 90 day share price return of 11.62% and year to date share price return of 14.80% point to recently fading momentum, while the 12.59% 1 year total shareholder return shows the longer term picture has been more supportive.

If you are looking beyond Agilent and want to see where money is moving in healthcare diagnostics and treatment, this is a good moment to check out 35 healthcare AI stocks

With the stock showing mixed recent returns, an intrinsic discount of about 11% and a roughly 37% gap to the average analyst target, the key question now is whether this is a genuine opportunity or if the market is already pricing in future growth.

Most Popular Narrative: 26.9% Undervalued

At a last close of $117.53 versus a narrative fair value of $160.69, Agilent Technologies is framed as undervalued, with that gap hinging on long term earnings power.

Strategic investments in higher margin recurring revenue streams including consumables, software, services, and digital platforms are gaining traction, with CrossLab and services delivering consistent mid single digit growth and high customer satisfaction, indicating further margin expansion and greater earnings stability in future periods.

Curious what sits behind that confidence in recurring revenue and margins? The narrative leans on specific revenue growth, profitability uplift, and a future earnings multiple. The numbers do the talking.

Result: Fair Value of $160.69 (UNDERVALUED)

However, you cannot ignore that higher tariffs and supply chain complexity, along with pressure on government and academic lab funding, could challenge the upbeat earnings narrative.

Next Steps

With sentiment this mixed, it helps to move fast and test the thesis against the data yourself, starting with the 4 key rewards.

Looking for more investment ideas?

If you stop with just one stock, you risk missing out on other opportunities that match your goals, so use the tools available and keep expanding your watchlist.

• Target potential mispricings by scanning companies that screen as high quality yet overlooked through the screener containing 25 high quality undiscovered gems.
• Prioritize staying power by checking stocks that pass the solid balance sheet and fundamentals stocks screener (46 results) for resilience and fundamentals that can support long term business strength.
• Boost your income focus by reviewing companies highlighted as 13 dividend fortresses that could help make your portfolio’s cash flow more robust.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.